Nephron Launches Asthma Inhaler Into Wide Open OTC Market
This article was originally published in The Tan Sheet
Nephron Pharmaceuticals makes its racepinephrine-containing Asthmanefrin, previously marketed only to health care professionals, available as the only OTC inhaler. The product likely will be alone on the market until Amphastar Pharmaceuticals’ planned launch in 2013 of a reformulated Primatene Mist inhaler.
You may also be interested in...
Armstrong Pharmaceuticals plans to submit in the fourth quarter an NDA to FDA for an OTC asthma inhaler reformulated without chlorofluorocarbon as a propellant. The House Energy and Power Subcommittee proposes allowing the firm to sell its remaining inventory of CFC-containing Primatene Mist.
The House Energy and Power Subcommittee July 18 will discuss draft legislation that would require EPA to allow sales of the remaining inventory of Armstrong Pharmaceutical’s CFC-propelled epinephrine inhalers, Primatene Mist.